Skip to main content
Publications
Tam S, Neslund-Dudas C, Barrett AM, Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis. Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Fermann GJ, Cash BD, Coelho-Prabhu N, Maegele M, Bingisser R, Sehgal V, Cohen AT, Golden AH, Russo J, Price M, Mangel A, Koch B, Christoph MJ, Milling, Jr. TJ. Definition of factor Xa inhibitor–related, life-threatening gastrointestinal bleeding and guidance on when to use reversal therapy: a Delphi panel. J Am Coll Emerg Physicians Open. 2023 Oct 2;4(5):e13043. doi: 10.1002/emp2.13043
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
van der Wall SJ, Teutsch C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, Franca LR, Lu S, Lip GYH, Huisman MV, GLORIA-AF Investigators. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF. TH Open. 2021 Feb 6;5(1):e35-42. doi: 10.1055/s-0040-1722706
Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Hoffman E, Mladsi DM, Cryer B, Hopkins W, Brater DC, Parikh R, Goyal R, Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data. Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).
Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B, Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab. Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).
Helliwell PS, Doward L, Whalley D, Tennant A, McKenna S, Reynolds S, Kay L, Spoorenberg A, van der Heijde Leeds D. Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis (AS). Poster presented at the 1999 ACR/ARHP Annual Scientific Meeting; November 14, 1999. Boston, MA. [abstract] Arthritis Rheumatol. 1999 Sep; 42(S9):s72.